Recent Updates
Recently added Catalysts
HROW Positive Sentiment

Harrow to Present at Two Investor Conferences in December

Key Takeaway: Harrow (Nasdaq: HROW) will participate in two investor conferences in December 2025. The first is the BTIG 5th Annual Ophthalmology Day on December 1, followed by the Piper Sandler 37th Annual Healthcare Conference on December 2. The latter will be webcast live, with a replay available for 90 days.
Price reaction · baseline $38.91 (2025-11-21 close) · hit pre-market · clean, no other HROW news in the window
day 0 close
+0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Harrow is actively engaging with investors through conferences.
  • Participation in reputable investor conferences enhances visibility.
  • The company showcases its commitment to ophthalmic disease management.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+67%
120-day peak, hindsight
Typical move
11.8%
average across 4 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
MELT-100
Phase 1 · Healthy Volunteers

Full Press Release Details

NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December:

BTIG 5thAnnual Ophthalmology Day (Virtual)Format: Fireside chatDate/Time: Monday, December 1, 2025, at 8:30 AM EST

Piper Sandler 37thAnnual Healthcare Conference (New York, NY)Format: Fireside chatDate/Time: Tuesday, December 2, 2025, at 3:00 PM EST

The fireside chat at Piper Sandler will be webcast live and can be found on the Event’s page on theCompany’s website. A replay will be available for approximately 90 days following the event.
About HarrowHarrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visitharrow.com.

Contacts:Mike BiegaVice President of Investor Relations and Communicationsmbiega@harrowinc.com617-913-8890

Frequently Asked Questions

When is Harrow's participation in investor conferences?

Harrow will participate in two conferences on December 1 and 2, 2025.

What format will the conferences take?

Both conferences will feature a fireside chat format.

Where can I watch the Piper Sandler conference?

The Piper Sandler conference will be webcast live on Harrow's website.

What is Harrow's focus in ophthalmic solutions?

Harrow provides solutions for various eye conditions, including dry eye and glaucoma.

Last updated: Nov 24, 2025